133 related articles for article (PubMed ID: 27027689)
1. Cobimetinib (Cotellic) for metastatic melanoma.
Med Lett Drugs Ther; 2016 Mar; 58(1491):43-4. PubMed ID: 27027689
[No Abstract] [Full Text] [Related]
2. A case of multi-metastatic melanoma with RAF1 fusion: a surprising response to anti-MEK therapy.
Pacaud A; Amintas S; Boussemart L; Cappellen D; Gérard E
Eur J Cancer; 2021 Apr; 147():161-163. PubMed ID: 33684875
[No Abstract] [Full Text] [Related]
3. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
4. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
5. Cometinib (Cotellic°) and metastic melanoma.
Prescrire Int; 2016 Dec; 25(177):293. PubMed ID: 30758925
[No Abstract] [Full Text] [Related]
6. MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients.
Patel U; Cornelius L; Anadkat MJ
JAMA Dermatol; 2015 Jan; 151(1):78-81. PubMed ID: 25426865
[TBL] [Abstract][Full Text] [Related]
7. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
8. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
9. Dermoscopic Evaluation of Melanocytic Nevi Changes With Combined Mitogen-Activated Protein Kinase Pathway Inhibitors Therapy for Melanoma.
Perier-Muzet M; Boespflug A; Poulalhon N; Caramel J; Breton AL; Thomas L; Dalle S
JAMA Dermatol; 2016 Oct; 152(10):1162-1164. PubMed ID: 27463731
[No Abstract] [Full Text] [Related]
10. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
11. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Shapiro GI; LoRusso P; Kwak E; Pandya S; Rudin CM; Kurkjian C; Cleary JM; Pilat MJ; Jones S; de Crespigny A; Fredrickson J; Musib L; Yan Y; Wongchenko M; Hsieh HJ; Gates MR; Chan IT; Bendell J
Invest New Drugs; 2020 Apr; 38(2):419-432. PubMed ID: 31020608
[TBL] [Abstract][Full Text] [Related]
12. Cobimetinib: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Oct; 75(15):1823-30. PubMed ID: 26452567
[TBL] [Abstract][Full Text] [Related]
13. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
14. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
[No Abstract] [Full Text] [Related]
15. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment.
Kouros P; Gerding H
Klin Monbl Augenheilkd; 2016 Apr; 233(4):488-9. PubMed ID: 27116515
[No Abstract] [Full Text] [Related]
17. MEK Retinopathy. Clinical case reports.
Rocha Cabrera P; Quijada Fumero E; Losada Castillo MJ; Abreu Reyes JA; Lorenzo Morales J
Arch Soc Esp Oftalmol (Engl Ed); 2018 Jan; 93(1):42-46. PubMed ID: 28506716
[TBL] [Abstract][Full Text] [Related]
18. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor.
Bickel A; Diem S; Flatz L; Stinn B; Siano M
J Cancer Res Ther; 2021; 17(1):276-278. PubMed ID: 33723170
[TBL] [Abstract][Full Text] [Related]
20. Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics.
Cheeti S; Deng Y; Chang I; Georgescu I; Templeton I; Choong N; Cheung KWK; Girish S; Musib L
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):144-152. PubMed ID: 32696585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]